Search

Displaying results 1491 - 1500 of 5925 in total
  1. Drug

    Taurine

    go.drugbank.com/drugs/DB01956
    ApprovedInvestigationalNutraceutical

    Taurine, whose chemical name is 2-aminoethanesulfonic acid, is one of the most abundant amino acids in several organs. It plays important role in essential biological processes. This conditional amino acid can be either be manufactured b...

    Mixtures: Aminosyn-PF, Aminosyn-PF
  2. Drug

    Zafirlukast

    go.drugbank.com/drugs/DB00549
    Approved

    Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed ...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Inhibitors
  3. Drug

    Sibeprenlimab

    go.drugbank.com/drugs/DB18919
    ApprovedInvestigational

    Sibeprenlimab is a Proliferation Inducing Ligand (APRIL) blocker. APRIL is a member of the tumour necrosis factor superfamily that regulates and modulates activated B cells. Elevated APRIL levels are often observed in inflammatory disord...

  4. Drug

    Calcium phosphate dihydrate

    go.drugbank.com/drugs/DB14481
    Approved

  5. Drug

    Serabelisib

    go.drugbank.com/drugs/DB14935
    Investigational

    Serabelisib is under investigation in clinical trial NCT02625259 (A Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics

  6. Drug

    Vopratelimab

    go.drugbank.com/drugs/DB15378
    Investigational

    Vopratelimab is under investigation in clinical trial NCT02904226 (JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors).

  7. Drug

    ATTO-1091

    go.drugbank.com/drugs/DB33956
    Experimental

    ATTO-1091 is under investigation in clinical trial NCT07819799 (Safety, Tolerability and PK of ATTO 1091 in Healthy Adult Volunteers and Patients With Ulcerative Colitis).

  8. Drug

    Osilodrostat

    go.drugbank.com/drugs/DB11837
    ApprovedInvestigational

    [A191850] Osilodrostat was approved for use in the EU in January 2020 for the treatment of endogenous Cushing's syndrome (i.e.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Inhibitors
  9. Drug

    Deleobuvir

    go.drugbank.com/drugs/DB14850
    Investigational

    Deleobuvir is under investigation in clinical trial NCT01983566 (Effect of Food and Increased Gastric pH Value on Bioavailability of a Single Dose of BI 207127 in Healthy Caucasian and Japanese Subjects

  10. Drug

    Ecallantide

    go.drugbank.com/drugs/DB05311
    Approved

    Apart from its FDA and EMA indication, ecallantide has been used off label in the management of nonhistaminergic angioedema, not due to HAE [A32017].